Patent application number | Description | Published |
20080233179 | TRANSDERMAL COMPOSITION HAVING ENHANCED COLOR STABILITY - A pharmaceutical composition for transdermal or transmucosal delivery of a pharmaceutical agent effective to treat a neurological disorder such as Parkinson's disease is disclosed. The composition contains an antioxidant, which provides color and chemical stability of the pharmaceutical agent. The antioxidant may also provide enhanced skin permeability of the agent. | 09-25-2008 |
20080260842 | PERMEATION ENHANCING COMPOSITIONS FOR ANTICHOLINERGIC AGENTS - A transdermal or topical skin-friendly composition including anticholinergic agents, such as oxybutynin, a urea-containing compound and a carrier system. A method is disclosed for treating a subject for urinary incontinence while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anticholinergics. | 10-23-2008 |
20090069364 | PHARMACEUTICAL COMPOSITIONS OF 5-ALPHA-REDUCTASE INHIBITORS AND METHODS OF USE THEREOF - Non-occlusive compositions for transdermal delivery of 5-alpha-reductase inhibitors, and more particularly finasteride or dutasteride or pharmaceutically acceptable salts or derivatives thereof, and methods of making same. The composition may, for example, be a gel suitable for transdermal or transmucosal applications. The compositions of the present invention typically include a mixture of water and alcohol, and a solvent system having a mono alkyl ether of diethylene glycol and a glycol present in specified ratios and in specific amounts, wherein the pH of the gel is usually between about pH 4.5 and about pH 8. The compositions may include further components, for example, the hydroalcoholic vehicle may further include additional penetration enhancer(s), buffering agent(s), antioxidant(s), stabilizer(s) and/or gelling agent(s). Also, a method for the sustained delivery of 5-alpha-reductase inhibitors to treat a variety of conditions and disorders. | 03-12-2009 |
20100216880 | TRANSDERMAL COMPOSITIONS FOR ANTICHOLINERGIC AGENTS - The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anticholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. A method is disclosed for treating a subject for urinary incontinence with these formulations while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anticholinergics. | 08-26-2010 |
20110195114 | TRANSDERMAL DELIVERY SYSTEMS FOR ACTIVE AGENTS - A delivery vehicle for topical pharmaceutical formulations that include a C2 to C4 alkanol, a polyalcohol, and a monoalkyl ether of diethylene glycol present in relative amounts sufficient to provide permeation enhancement of an active agent through mammalian dermal or mucosal surfaces. Preferably, the delivery vehicle as well as the formulations that contain it are substantially free of long-chain fatty alcohols, long-chain fatty acids and long-chain fatty esters in order to avoid potential undesirable odor and irritation effects caused by such compounds during use of the formulation. Without these additives, use of the formulations is facilitated and patient compliance is greater | 08-11-2011 |
20110245215 | TRANSDERMAL DELIVERY SYSTEMS FOR ACTIVE AGENTS - A formulation for transdermal or transmucosal administration of an active agent. The formulation includes an active agent and a delivery vehicle comprising a C | 10-06-2011 |
20110257141 | TRANSDERMAL PHARMACEUTICAL FORMULATION FOR MINIMIZING SKIN RESIDUES - This invention relates to novel transdermal or transmucosal pharmaceutical formulation having an active agent of testosterone which reduces the occurrences of contamination of other individuals and the transference to clothing of the user. The solvent system of the formulation includes a monoalkylether of diethylene glycol and a glycol present in specified ratios, and a mixture of water and alcohol. The invention also relates to a method for inhibiting or delaying crystallization of the active agent in a pharmaceutical formulation. | 10-20-2011 |
20120294934 | TRANSDERMAL COMPOSITIONS FOR ANTICHOLINERGIC AGENTS - The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anti-cholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. A method is disclosed for administering such formulations to a person in need thereof while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anti-cholinergics. | 11-22-2012 |
20130045953 | NESTORONE.RTM./ESTRADIOL TRANSDERMAL GEL - The invention discloses compositions and methods for ensuring in both women of fertile age where it ensures also a contraception with additional health benefits and in postmenopausal women where it offers a hormonal therapy with additional medical benefits such as the potential for lower risk of thrombosis. The aforementioned compositions comprising NES as a potent progestational and antiovulatory agent with no androgenic nor estrogenic nor glucocorticoid effect, and combined with estradiol formulated for non-oral transdermal administration as specific daily doses. | 02-21-2013 |
20130295166 | TESTOSTERONE FORMULATIONS - The subject invention provides improved testosterone gel formulations. | 11-07-2013 |